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Abstract
Aims Women with heart failure are typically older, and
more often have hypertension and a preserved left ven-
tricular ejection fraction as compared with men. We sought
to analyze if these sex differences influence the course and
outcome of acute heart failure.
Methods and results We analyzed sex differences in acute
heart failure in 1161 patients enrolled in the RELAX-AHF
study. The pre-specified study endpoints were used. At
baseline, women (436/1161 patients) were older, had a
higher left ventricular ejection fraction, a higher rate of
hypertension, and were treated differently from men. Early
dyspnea improvement (moderate or marked dyspnea
improvement measured by Likert scale during the first
24 h) was greater in women. However, dyspnea improve-
ment over the first 5 days (change from baseline in the
visual analog scale area under the curve (VAS AUC) to day
5) was similar between men and women. Women reported
greater improvements in general wellbeing by Likert, but
no such benefits were evident with the VAS score. Multi-
variable predictors of moderate or marked dyspnea
improvement were female sex (p = 0.0011), lower age
(p = 0.0026) and lower diuretic dose (p = 0.0067). The
additional efficacy endpoints of RELAX-AHF were similar
between men and women and serelaxin was equally
effective in men and women.
Conclusions Women exhibit better earlier dyspnea relief
and improvement in general wellbeing compared with men,
even adjusted for age and left ventricular ejection fraction.
However, in-hospital and post-discharge clinical outcomes
were similar between men and women.
This trial is registered at ClinicalTrials.gov,
NCT00520806.
Keywords Serelaxin  Acute heart failure  Sex  Gender 
Dyspnea
Introduction
Women and men show marked differences both in the
onset of heart failure and in established chronic heart
failure [1, 2]. We recently showed that clinical character-
istics of men and women admitted for acute heart failure
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are also different [3]. Relative to men, women typically
more often show features such as hypertension, atrial fib-
rillation and preserved left ventricular ejection fraction,
whereas men usually present with ischemic heart disease,
history of myocardial infarction, reduced left ventricular
ejection fraction, and specific medical and device treatment
[3].
In previous studies, women admitted for acute heart
failure received lower oral and intravenous diuretic doses,
had fewer dose increases, lost less body weight during
hospitalization, and had a longer length of hospitalization
compared with men [3, 4]. However, no studies have
specifically focused on differences in dyspnea relief and
changes in general wellbeing between men and women
admitted for acute heart failure.
Here, we investigate sex differences in early and per-
sistent dyspnea relief as well as additional efficacy end-
points, and analyzed patient features and heart failure
characteristics in men and women hospitalized for acute
heart failure enrolled in the RELAX-AHF study [5]. The
RELAX-AHF study tested the effects of serelaxin, a
recombinant form of the natural hormone human relaxin 2,
vs. placebo on dyspnea relief on top of standard of care [5],
and provided insights into specific effects of serelaxin in
acute heart failure [6, 7].
Patients and methods
Study design, population and treatment
The RELAX-AHF study was a multi-center, double-blind,
randomized, controlled trial, comparing the intravenous
administration of serelaxin for up to 48 h vs. placebo on
top of standard of care. Patients were randomized within
the initial 16 h of hospital admission for AHF with con-
gestion and dyspnea, additionally having elevated natri-
uretic peptide levels, mild to moderate renal dysfunction,
and systolic blood pressure[125 mmHg. Notably, patient-
reported dyspnea improvement was evaluated by the two
primary efficacy endpoints of the RELAX-AHF study: first,
change from baseline to day 5 in the visual analog scale
area under the curve (VAS AUC) and, second, the pro-
portion of patients with moderate or marked dyspnea
improvement as indicated by Likert scale ratings at 6, 12
and 24 h (all three), both analyzed by intention to treat [5].
The VAS was a 0–100-mm long scale on which each
patient marked the level of dyspnea and the distance from
the 0-level of the scale was measured. VAS appropriately
allows quantification of within-subject changes of repeated
measurements as it has the sensitivity required to measure
changes. The 7-item Likert scale is a psychometric
instrument for the grading of dyspnea. Patients were asked
to rate the degree of improvement in response to therapy
within the spectrum of categories ranging from markedly
better to markedly worse. Notably, for the patients with
available dyspnea Likert assessments, those following
death, worsening heart failure or heart failure/renal failure
rehospitalization event were imputed as the worst score of
the Likert scale as ‘markedly worse’ (worse Likert
score = -3); for the ‘‘Time to Moderately or Markedly
Better Dyspnea Through Day 5’’ analyses, for patients who
died, had worsening heart failure or re-hospitalization due
to heart failure, the day was set to 6 days.
Ethics
The RELAX-AHF study was approved by all local Ethics
Committees and complied with the Declaration of Helsinki
guidelines. Written informed consent was obtained from all
patients.
Statistical analyses
1161 patients were randomized in RELAX-AHF [the
Intent-to-Treat (ITT) population]. For outcomes with
complete data, the analysis included all randomized
patients (n = 1161). For other outcomes, cases with
missing outcome data were omitted from the analysis under
an assumption of missing at random. Missing values in
baseline covariates were imputed using treatment-specific
medians for continuous variables and treatment-specific
modal values for categorical variables. The criterion for
statistical significance is p B 0.05 two-tailed for all anal-
yses. Patient baseline characteristics, symptomatic
response, diuretic doses, treatment response, and post-dis-
charge outcomes were compared by sex using t tests for
continuous variables, Chi squared tests or Fisher’s exact
tests for categorical variables, and log-rank tests for time-
to-event outcomes. Effects of treatment by sex interaction
on clinical outcomes were examined using multiple linear
regression models for continuous endpoints, logistic
regression models for categorical endpoints, and Cox pro-
portional hazards models for time-to-event endpoints.
Three-way interaction effects of sex, treatment, and EF
status on clinical outcomes were also examined using the
same approach. A multi-variable logistic regression model
was used to assess the association between moderately or
markedly better dyspnea on the Likert scale at 6, 12 and
24 h and selected baseline characteristics, including sex,
HFpEF status as defined by ESC-guideline criteria [8], age,
pulse pressure, heart rate, and loop diuretic dose. The effect
of treatment by sex interaction on markedly or moderately
improved dyspnea at each time point (6, 12 and 24 h) was
also estimated using logistic regression models. Repeated
measures ANOVA models were used to estimate mean
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changes in biomarkers (hs-troponin-T, NT-proBNP and
cystatin-C) from baseline through day 14, mean changes in
patient-reported dyspnea according to visual analog scale
from baseline to day 5, and mean total daily dose of IV
diuretics (mg) from day 1 to day 5, stratified by treatment
and sex. A linear regression model was used to estimate the
effects of treatment, sex and their interaction on total dose
of IV diuretics from day 1 to day 5. Fisher’s exact tests
were used to assess the association between treatment and
physician-assessed signs and symptoms of congestion at
day 2 for each sex. Effects of treatment by sex interaction
on physician-assessed signs and symptoms of congestion at
day 2 were evaluated using proportional-odds logistic
regression models. Kaplan–Meier survival curves for CV
mortality through day 180 were generated for all sex and
treatment combinations, and compared using log-rank
tests. A Cox proportional hazard model was used to
examine the treatment effect by sex.
Analyses were performed by the Statistical Analysis
Center at Columbia University.
Results
Baseline characteristics
Details of baseline patient characteristics are shown in
Table 1. The RELAX-AHF study comprised 725 men and
436 women. Women were on average 6 years older, had
about 10% higher LVEF and a lower proportion of LVEF
\40%, and had less frequent ischemic heart disease or a
history of chronic heart failure one month prior. Before
hospitalization, women had lower NYHA class symptoms
and they more often had hypertension, while less fre-
quently being cigarette smokers or showing peripheral
vascular disease, asthma, bronchitis, or COPD, myocardial
infarction and history of CRT or ICD procedures and
implanted devices. Women less often received oral loop
diuretics 30 days before study entry and were more often
treated with digoxin. Plasma levels of hemoglobin, crea-
tinine, uric acid, troponin and estimated glomerular filtra-
tion rate were lower in women, whereas they had higher
levels of total cholesterol. There were no significant sex
differences in clinical variables or congestion.
Symptomatic response by sex
Details on the symptomatic response by sex are shown in
Table 2 and Fig. 1.
The change from baseline in dyspnea visual analog scale
AUC to day 5 primary dyspnea endpoint did not vary by sex.
However, there was a significantly higher proportion of
women than men with moderate or marked dyspnea
improvement measured by Likert scale during the first 24 h,
which was the other primary endpoint in RELAX-AHF.
Likewise, the change from baseline in dyspnea visual
analog scale score was not different in women compared to
men. But there were consistently higher rates of women with
markedly or moderately improved dyspnea per Likert scale
and higher general wellbeing Likert score values in women,
both through 24 h and through 5 days, respectively.
Diuretic doses, treatment response and post-
discharge outcome by sex
Details on the diuretic doses, treatment response and post-
discharge outcome by sex are shown in Table 3. Women
were treated with lower total IV and oral loop diuretic
doses through day 5, respectively (Fig. 2), but dyspnea
improved earlier moderately or markedly through day 5 in
women. There were no relevant sex differences regarding
changes in neither body weight nor relative body weight,
worsening heart failure and outcome (Fig. 3), but women
showed a trend towards longer ICU/CCU stays [mean
(SD), 4.05 (7.67) days vs. 3.51 (6.63) days, p = 0.0248]
and total initial hospital stays [10.37 (9.62) days vs. 9.87
(9.17) days, p = 0.0258] compared to men.
Interaction analyses of differential effects by sex
Physician-assessed signs and symptoms of congestion,
such as dyspnea on exertion, orthopnea, edema or rales, did
not vary by treatment and sex (Fig. 4). Moreover, women
did not show different outcome than men in any of the
analyzed endpoints. Neither did the relationship of sex with
outcome vary by treatment with serelaxin, the presence of
heart failure with preserved ejection fraction or both
characteristics.
Effect of selected characteristics on early dyspnea
improvement
A multi-variable logistic regression model was built to
assess the association between moderately or markedly
better dyspnea on the Likert scale at 6, 12 and 24 h using
selected baseline characteristics, such as sex, HF status,
age, pulse pressure, heart rate, and loop diuretic dose as
covariates (Table 4). Male sex, age and total diuretic dose
showed independent negative association with dyspnea
improvement within 24 h.
Changes in biomarkers
The changes of hs-troponin-T, NT-proBNP, and cystatin-C
from baseline to day 2, 5, and 14 in men and women are
presented in Fig. 5. Both, men and women, showed a
282 Clin Res Cardiol (2017) 106:280–292
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Table 1 Baseline characteristics by sex (n = 1161)
Variables Totala (n = 1161) Mena (n = 725) Womena (n = 436) p valueb
Demographics and HF characteristics
Age (years) 72.0 (11.2) 69.8 (11.7) 75.8 (9.2) \0.0001 [S]
Serelaxin administration (%) 581 (50.0%) 368 (50.8%) 213 (48.9%) 0.5295 [2]
White 1096 (94.4%) 680 (93.8%) 416 (95.4%) 0.2450 [2]
Geographic region 0.0001 [2]
Eastern EU 562 (48.4%) 315 (43.4%) 247 (56.7%)
Western EU 204 (17.6%) 144 (19.9%) 60 (13.8%)
South America 71 (6.1%) 45 (6.2%) 26 (6.0%)
North America 114 (9.8%) 85 (11.7%) 29 (6.7%)
Israel 210 (18.1%) 136 (18.8%) 74 (17.0%)
US-Likec 786 (67.7%) 540 (74.5%) 246 (56.4%) \0.0001 [2]
Left ventricular EF (%) 38.6 (14.6) 35.1 (13.2) 44.7 (14.9) \0.0001 [S]
EF\40% 598 (54.8%) 446 (64.8%) 152 (37.7%) \0.0001 [2]
Ischemic heart disease 603 (51.9%) 419 (57.8%) 184 (42.2%) \0.0001 [2]
Time to randomization (h) 7.9 (4.6) 7.7 (4.8) 8.2 (4.4) 0.0384 [1]
CHF 1 month prior 861 (74.2%) 557 (76.8%) 304 (69.7%) 0.0074 [2]
HF hospitalization past year 397 (34.2%) 260 (35.9%) 137 (31.4%) 0.1225 [2]
NYHA class 30 days before admission 0.0014 [2]
I 323 (28.1%) 186 (25.8%) 137 (31.8%)
II 304 (26.4%) 174 (24.2%) 130 (30.2%)
III 389 (33.8%) 268 (37.2%) 121 (28.1%)
IV 135 (11.7%) 92 (12.8%) 43 (10.0%)
Clinical variables
Body mass index (kg/m2) 29.3 (5.7) 29.3 (5.3) 29.3 (6.3) 0.8964 [S]
Syst. blood pressure (mmHg) 142.2 (16.6) 141.2 (16.5) 143.8 (16.7) 0.0110 [1]
Diast. blood pressure (mmHg) 79.0 (14.2) 79.8 (14.0) 77.7 (14.5) 0.0125 [1]
Heart rate (beats/min) 79.7 (14.9) 79.1 (14.5) 80.6 (15.6) 0.1093 [1]
Respiratory rate (breaths/min) 21.9 (4.6) 21.7 (4.6) 22.3 (4.6) 0.0299 [1]
Congestion at baseline
Edema 910 (78.9%) 578 (80.4%) 332 (76.3%) 0.1010 [2]
Orthopnea 1106 (95.8%) 689 (95.8%) 417 (95.9%) 0.9773 [2]
JVP 850 (75.5%) 533 (76.0%) 317 (74.6%) 0.5845 [2]
Dyspnea on exertion 1136 (99.6%) 708 (99.7%) 428 (99.5%) 0.6351 [3]
Dyspnea by VAS 44.2 (20.0) 44.7 (19.9) 43.4 (20.1) 0.2839 [1]
Rales 1095 (94.8%) 679 (94.3%) 416 (95.6%) 0.3249 [2]
Comorbidities
Hypertension 1006 (86.6%) 602 (83.0%) 404 (92.7%) \0.0001 [2]
Hyperlipidemia 617 (53.1%) 405 (55.9%) 212 (48.6%) 0.0167 [2]
Diabetes mellitus 551 (47.5%) 347 (47.9%) 204 (46.8%) 0.7229 [2]
Cigarette smoking 153 (13.2%) 127 (17.5%) 26 (6.0%) \0.0001 [2]
Stroke or other cerebrovascular event 157 (13.5%) 101 (13.9%) 56 (12.8%) 0.5999 [2]
Peripheral vascular disease 155 (13.4%) 115 (15.9%) 40 (9.2%) 0.0012 [2]
Asthma, bronchitis, or COPD 184 (15.8%) 138 (19.0%) 46 (10.6%) 0.0001 [2]
Atrial fibrillation at screening 479 (41.3%) 284 (39.2%) 195 (44.8%) 0.0608 [2]
History of atrial fibrillation or flutter 602 (51.9%) 354 (48.8%) 248 (56.9%) 0.0078 [2]
History of CRT or ICD procedures 294 (25.3%) 218 (30.1%) 76 (17.4%) \0.0001 [2]
Myocardial infarction 403 (34.7%) 286 (39.4%) 117 (26.8%) \0.0001 [2]
Depression 60 (5.2%) 34 (4.7%) 26 (6.0%) 0.3425 [2]
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marked early decrease of NT-proBNP levels during the first
2 days of treatment. These levels further decreased in both
sexes through day 5 and persisted through day 14. NT-
proBNP changes were paralleled by increasing levels of
cystatin-C in both sexes by day 5 and day 14. The levels of
hs-troponin-T decreased through days 5 and 14 in men and
women.
Discussion
Marked or moderate early dyspnea improvement using the
7-item Likert scale was seen more often in women
admitted for acute heart failure within the first 24 h, and
persisted over the first 5 days. These improvements were
not paralleled by the VAS-scale assessments. Similarly,
Table 1 continued
Variables Totala (n = 1161) Mena (n = 725) Womena (n = 436) p valueb
Devices
Pacemaker 121 (10.4%) 70 (9.7%) 51 (11.7%) 0.2701 [2]
Implantable cardiac defibrillator 154 (13.3%) 136 (18.8%) 18 (4.1%) \0.0001 [2]
Biventricular pacing 113 (9.7%) 96 (13.2%) 17 (3.9%) \0.0001 [2]
Medication
ACE inhibitor 633 (54.5%) 392 (54.1%) 241 (55.3%) 0.6894 [2]
ACEi or ARBs 788 (67.9%) 492 (67.9%) 296 (67.9%) 0.9922 [2]
Angiotensin-receptor blocker 185 (15.9%) 112 (15.4%) 73 (16.7%) 0.5594 [2]
Beta-blocker 794 (68.4%) 507 (69.9%) 287 (65.8%) 0.1451 [2]
Aldosterone antagonist 365 (31.4%) 240 (33.1%) 125 (28.7%) 0.1151 [2]
Oral loop diuretic 30 days prior 44.7 (65.2) 50.5 (72.3) 34.9 (49.6) \0.0001 [S]
Digoxin 228 (19.6%) 116 (16.0%) 112 (25.7%) \0.0001 [2]
Nitrates at randomization 81 (7.0%) 42 (5.8%) 39 (8.9%) 0.0412 [2]
Baseline laboratory data
Sodium (mmol/L) 140.82 (3.59) 140.76 (3.60) 140.93 (3.57) 0.4183 [1]
Phosphate (mmol/L) 1.19 (0.32) 1.18 (0.36) 1.20 (0.23) 0.3547 [S]
Calcium (mmol/L) 2.26 (0.15) 2.26 (0.16) 2.27 (0.14) 0.8622 [S]
Hemoglobin (g/dL) 12.79 (1.86) 13.11 (1.89) 12.27 (1.68) \0.0001 [S]
White blood cell count (910/L) 8.179 (2.843) 8.022 (2.637) 8.439 (3.142) 0.0243 [S]
Lymphocyte (%) 18.17 (7.81) 18.50 (7.81) 17.64 (7.78) 0.0803 [1]
Potassium (mmol/L) 4.27 (0.63) 4.31 (0.64) 4.21 (0.61) 0.0098 [1]
Creatinine (lmol/L) 116.58 (33.15) 126.28 (32.81) 100.58 (26.94) \0.0001 [S]
Uric acid (lmol/L) 475.8 (135.9) 488.1 (137.7) 455.4 (130.6) \0.0001 [1]
Troponin T (lg/Ld) 0.035 (0.033, 0.037) 0.037 (0.035, 0.040) 0.031 (0.029, 0.034) 0.0015 [S]
BUN (mmol/L) 9.78 (4.03) 10.01 (3.96) 9.40 (4.10) 0.0132 [1]
Cystatin-C (mg/Ld) 1.45 (1.43, 1.48) 1.46 (1.43, 1.49) 1.44 (1.40, 1.48) 0.4950 [1]
Alanine aminotransferase (U/Ld) 23.5 (22.7, 24.4) 23.8 (22.7, 25.0) 23.1 (21.8, 24.5) 0.4078 [1]
NT-proBNP (ng/Ld) 5054 (4795, 5326) 4936 (4615, 5279) 5253 (4830, 5714) 0.2579 [1]
eGFR (mL/min per 1.73 m2) 53.49 (13.03) 54.81 (12.84) 51.32 (13.06) \0.0001 [1]
Total cholesterol (mmol/L) 4.09 (1.17) 3.97 (1.13) 4.30 (1.20) \0.0001 [1]
Glucose (mmol/L) 7.75 (3.57) 7.62 (3.48) 7.96 (3.71) 0.1202 [1]
Albumin (g/L) 40.23 (4.33) 40.28 (4.57) 40.15 (3.91) 0.6229 [S]
a Mean (SD), or geometric mean (95% CI) if log transformed, for continuous variables, n (%) for categorical variables (% based on total number
of patients with a non-missing value of the characteristic)
b Based on t test [1], Chi squared test [2], Fisher’s exact test [3], or the Satterthwaite method due to unequal variances in comparison groups [S]
c US-Like in the analyses indicates Region 1 vs. Region 2. Region 1 includes patients from United States, France, The Netherlands, Israel, Spain,
Germany, Italy, and Poland. Region 2 includes patients from Argentina, Hungary, and Romania
d The following baseline laboratory variables have been log transformed: alanine aminotransferase, NT-proBNP, troponin T, cystatin-C
284 Clin Res Cardiol (2017) 106:280–292
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general wellbeing, using the Likert scale over the first
5 days, improved significantly better in women, but this
was not seen when the VAS wellbeing score was used.
Other clinical outcome parameters were similar between
men and women, and serelaxin was equally effective in
men and women.
Dyspnea improvement by sex
Dyspnea is a complex symptom in patients with acute heart
failure. Patient-reported dyspnea relief is a clinically
meaningful treatment goal because persistent dyspnea is
associated with adverse outcome [9, 10]. It is advocated as
a patient-relevant endpoint for heart failure trials by reg-
ulatory authorities [11].
Therefore, our findings that women have a greater early
dyspnea relief may be of clinical relevance. Although this
difference could likely be explained by factors related to
female sex, such as hypertension and heart failure with
preserved ejection fraction (HFpEF), our multivariable
analysis showed that female sex was an independent pre-
dictor of early dyspnea relief. No sex differences in dysp-
nea relief between men and women were found in a post
hoc analysis of the PROTECT pilot study. However,
Table 2 Symptomatic response
by sex
Total cohorta (n = 1161) Mena (n = 725) Womena (n = 436) p valueb
Change from baseline VAS score (mm)
Hour 6 9.55 (16.51) 8.92 (16.21) 10.60 (16.97) 0.0933 [1]
Hour 12 14.20 (19.33) 13.35 (19.74) 15.63 (18.57) 0.0518 [1]
Day 1 18.74 (23.49) 17.77 (23.35) 20.35 (23.66) 0.0701 [1]
Day 2 22.35 (26.55) 21.46 (27.02) 23.82 (25.70) 0.1420 [1]
Day 5 25.94 (30.77) 24.88 (31.02) 27.68 (30.30) 0.1334 [1]
Day 14 22.72 (34.52) 22.01 (34.56) 23.90 (34.46) 0.3661 [1]
Dyspnea VAS AUC (mm 9 h)
Baseline to day 14 7786.82 (9333.49) 7482.07 (9410.64) 8293.56 (9192.12) 0.1515 [1]
Day 1 to day 5 2234.37 (2549.18) 2137.14 (2566.48) 2396.04 (2514.75) 0.0938 [1]
Day 1 to day 14 7489.24 (9077.60) 7201.79 (9152.91) 7967.23 (8940.94) 0.1642 [1]
Dyspnea markedly or moderately improved per Likert scale, n (%)
Hour 6 385 (33.6%) 221 (31.0%) 164 (38.0%) 0.0156 [2]
Hour 12 544 (47.5%) 313 (43.8%) 231 (53.5%) 0.0015 [2]
Day 1 751 (65.5%) 443 (62.0%) 308 (71.1%) 0.0017 [2]
Day 2 850 (74.0%) 510 (71.3%) 340 (78.5%) 0.0070 [2]
Day 5 915 (79.5%) 555 (77.4%) 360 (82.9%) 0.0240 [2]
Day 14 857 (74.4%) 523 (72.8%) 334 (77.0%) 0.1208 [2]
General wellbeing, change from baseline in VAS score (mm)
Hour 6 9.12 (16.48) 8.63 (16.12) 9.93 (17.06) 0.1933 [1]
Hour 12 13.61 (18.85) 13.04 (18.64) 14.56 (19.19) 0.1843 [1]
Day 1 18.20 (22.72) 17.45 (22.14) 19.44 (23.63) 0.1491 [1]
Day 2 21.19 (25.77) 20.47 (25.86) 22.39 (25.61) 0.2194 [1]
Day 5 24.82 (30.43) 23.50 (30.25) 27.00 (30.64) 0.0579 [1]
Day 14 21.35 (33.67) 20.48 (33.28) 22.81 (34.30) 0.2530 [1]
General wellbeing Likert score
Hour 6 0.99 (1.11) 0.94 (1.09) 1.07 (1.12) 0.0324 [W]
Hour 12 1.31 (1.17) 1.23 (1.19) 1.44 (1.13) 0.0018 [W]
Day 1 1.60 (1.36) 1.53 (1.36) 1.71 (1.35) 0.0040 [W]
Day 2 1.75 (1.49) 1.64 (1.55) 1.91 (1.38) 0.0012 [W]
Day 5 1.84 (1.77) 1.77 (1.83) 1.97 (1.67) 0.0434 [W]
Day 14 1.56 (2.07) 1.51 (2.11) 1.65 (2.01) 0.3751 [W]
a Mean (SD) for continuous variables and n (%) for categorical variables (% based on total number of
patients with a non-missing value of the characteristic)
b Based on t tests [1] for continuous variables, and Chi squared tests [2] for categorical variables. Wilcoxon
Rank Sum test [W] will be performed for general wellbeing Likert score
Clin Res Cardiol (2017) 106:280–292 285
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patient numbers were small and no adjustments for pre-
served left ventricular ejection fraction were made [12].
Comparable studies of early dyspnea relief in acute heart
failure patients have not considered sex as covariate [10].
The underlying cause of our findings is likely multifac-
torial. Remarkably, more intense dyspnea relief in women
occurred despite using lower total IV and oral loop diuretic
doses and less weight loss through day 5 inwomen compared
to men, and comparable drops of NT-proBNP values were
seen in both sexes. These findings can be explained patho-
physiologically by a typical mechanism of cardiac decom-
pensation in women, which is frequently caused by fluid
redistribution and related to the higher proportion of HFpEF
and hypertension among women [13]. In this context, the
slightly higher proportion of women being treated with
intravenous nitrates during the first days of treatment could
have favored the faster improvement of dyspnea in women.
However, the absolute numbers of patients who were treated
with intravenous inotrope/vasoactive medication were rela-
tively low and it appears unlikely that this fully explains the
differential dyspnea response by sex.
Theoretically, the higher rates of concomitant pul-
monary disease, such as asthma, bronchitis, or COPD, in
men, might have negatively affected dyspnea response in
men. However, patients with relevant severity of these
diseases were not included in the trial based on the
exclusion criteria. Also, less diuretic treatment and less
weight loss could be required in women to reach com-
parable outcome and better symptomatic relief. It is evi-
denced by trial results and registry data in acute heart
failure that the overall outcome does not differ between
men and women despite significantly lower diuretic doses
and less absolute weight loss [3, 14]. It should be noted
that all measured surrogates of congestion at baseline,
such as edema, orthopnea, jugular venous pressure,
dyspnea on exertion, and rales, were well balanced
between men and women. Thus, it might be speculated
that different symptom perception per se is responsible for
the higher rates of moderate to marked dyspnea relief in
women over men. Alternatively, underlying pathophysio-
logical differences in fluid distribution may have trans-
lated to differences in symptoms. An acute
cardiovascular, hypertensive type of failure has been
proposed as subtype of acute heart failure [13]. It is
common in the elderly, patients with history of hyper-
tension, and women, and is characterized by preserved
left ventricular ejection fraction [13]. In this type of heart
failure, ventricular and vascular stiffness play important
pathophysiological roles, with a vulnerability to any dis-
order of fluid balance, resulting in a rapid increase of
vascular resistance, blood pressure and increased pul-
monary pressure [13]. Notably, the increase in pulmonary
arterial pressure and the pulmonary capillary wedge
pressure was previously identified as major determinants
of dyspnea in an analysis of the hemodynamics of acute
heart failure patients [15]. Because data from community
dwelling subjects have proven that women have greater
aortic stiffening and lower total arterial compliance than
men [16], it might be speculated that rapid changes of
intracardiac and intrapulmonary pressures as surrogates
for dyspnea depend, to a greater extent, on changes of
vascular volume load in women than in men. This could
explain why early vasoactive and decongestive therapy
might have more intense effects in women than in men,
and that this could translate into differences in perceived
dyspnea relief. These effects are more likely to be pro-
nounced early during standard treatment, when the most
intense reduction of vascular resistance and ventricular
afterload is usually seen in acute heart failure patients
[15].
Fig. 1 Dyspnea Likert scale (a) and VAS AUC change (b) by treatment and sex
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The question why marked or moderate early dyspnea
improvement was seen more often in women using the
7-item Likert scale and not by the VAS-scale assessments
could be due to the different aspects that are covered by the
two different measurement scales. Notably, the Likert scale
was used to assess early (6–24 h) dyspnea relief, whereas
the VAS-scale was used to quantify persistent dyspnea
relief by the change in VAS area under the curve (VAS
AUC) through day 5, as specified in the study protocol
[17]. The MEASURE-HF study indicated that the Likert
Table 3 Inotrope/vasoactive medication, diuretic doses, treatment response and post-discharge outcome by sex
Total cohorta
(n = 1161)
Mena
(n = 725)
Womena
(n = 436)
p valueb
Inotrope/vasoactive medication
All IV inotrope/vasoactive agents through day 5 161 (13.9) 93 (12.8) 68 (15.6) 0.1862 [C]
Nitroglycerin 127 (10.9) 66 (9.1) 61 (14.0) 0.0098 [C]
Diuretic doses and treatment response
Total IV loop diuretic dose through day 5 (mg) 187.21 (316.02) 215.36 (364.91) 140.76 (204.10) \0.0001
[S]
Total oral loop diuretic dose through day 5 (mg) 187.70 (191.79) 199.12 (204.05) 168.86 (168.20) 0.0067 [S]
Treatment response
Study day of moderately or markedly improved dyspnea through day 5 1.72 (2.00) 1.87 (2.07) 1.48 (1.85) 0.0005 [W]
Study day of worsening HF through day 5 5.65 (1.19) 5.61 (1.25) 5.71 (1.08) 0.1395 [W]
Worsening HF through day 14 157 (13.56%) 106 (14.67%) 51 (11.71%) 0.1522 [L]
Change in bodyweight from baseline (kg)
Day 1 -1.48 (1.98) -1.56 (2.11) -1.33 (1.73) 0.0433 [S]
Day 2 -2.03 (2.46) -2.13 (2.65) -1.87 (2.09) 0.0752 [S]
Day 5 -2.86 (3.34) -2.93 (3.50) -2.76 (3.05) 0.4210 [S]
Day 14 -3.31 (4.26) -3.49 (4.60) -3.02 (3.64) 0.0642 [S]
Relative change in bodyweight from baseline (%)
Day 1 -1.82 (2.38) -1.83 (2.44) -1.81 (2.28) 0.8637 [1]
Day 2 -2.48 (2.90) -2.45 (2.97) -2.53 (2.80) 0.6483 [1]
Day 5 -3.46 (3.91) -3.30 (3.84) -3.72 (4.01) 0.0797 [1]
Day 14 -3.87 (4.75) -3.82 (4.89) -3.95 (4.53) 0.6780 [1]
Outcome
Uncontrolled blood pressurec 271 (23.3%) 157 (21.7%) 114 (26.1%) 0.0798 [C]
Length of ICU/CCU stay (days) 3.71 (7.04) 3.51 (6.63) 4.05 (7.67) 0.0248 [W]
Length of initial hospital stay (days) 10.06 (9.34) 9.87 (9.17) 10.37 (9.62) 0.0258 [W]
Days alive and out of hospital before day 30 20.61 (6.64) 20.68 (6.80) 20.47 (6.38) 0.1001 [W]
Death or worsening HF or readmission to hospital for HF through day
30
200 (17.30%) 129 (17.87%) 71 (16.34%) 0.4556 [L]
CV death or readmission to hospital for HF or renal failure through
day 30
83 (7.20%) 50 (6.95%) 33 (7.62%) 0.6769 [L]
CV death or readmission to hospital for HF or renal failure through
day 30 after discharge
92 (8.17%) 55 (7.82%) 37 (8.76%) 0.5790 [L]
All-cause death through day 30 31 (2.68%) 16 (2.22%) 15 (3.46%) 0.2100 [L]
All-cause death or readmission to hospital for HF or renal failure
through day 60
154 (13.36%) 97 (13.48%) 57 (13.17%) 0.9028 [L]
CV death through day 180 88 (7.68%) 57 (7.98%) 31 (7.20%) 0.6484 [L]
All-cause death through day 180 107 (9.31%) 68 (9.46%) 39 (9.06%) 0.8059 [L]
a Mean (SD) for continuous variables; n (%) for categorical variables (% based on total number of patients with a non-missing value of the
characteristic); and number of events (K-M%) for time-to-event variables
b Based on Satterthwaite method [S] (if equal variance assumption violated) for continuous variables, Wilcoxon rank sum test [W] for count
variables, Chi squared test [C] for categorical variables, and logrank test [L] for time-to-event variables
c Uncontrolled blood pressure is defined as systolic[150 mmHg or diastolic[90 mmHg at day 2 and through day 5, or at time of discharge (if
discharge time Bday 5), whichever occurs first
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scale categories reflect initial improvement relative to the
baseline status without capturing relevant improvement at
later timepoints; contrarily, VAS scores of dyspnea
improved steadily [18]. Likert scale assessment emphasizes
the change of perceived dyspnea compared to the most
severe symptom sensation at baseline. The effect is more
clearly measurable as an improvement on its categorical
scale with higher initial symptom severity, but it is
increasingly difficult to be captured as more time passes
by. VAS scores capture the particular instantaneous state of
dyspnea on a continuous scale individually at different
timepoints. However, it is noteworthy that a trend towards
higher change from baseline VAS score (mm) in women
compared to men was detectable at the time points 6 and
12 h and after 1 day (p = 0.0933, p = 0.0518 and
p = 0.0701, respectively) which also translated to a trend
toward higher change from dyspnea VAS AUC (mm 9 h)
from day 1 to day 5 (p = 0.0938) in women.
Serelaxin effects in men and women
Although relaxin is commonly known to exert various
biologic effects in women during pregnancy [19, 20], data
on sex-specific cardio-vascular effects are scarce. Debrah
et al. demonstrated in a rat model that recombinant relaxin
increases cardiac output and reduces arterial load in both
male and female rats [21]. In a recent subgroup analysis, it
was shown that serelaxin was equally effective in men and
women [22]. The results of our interaction analyses con-
firm that sex does not modify the effects of serelaxin on
dyspnea relief and/or any death- or rehospitalization-re-
lated outcomes in men and women.
Fig. 2 Total daily dose of IV diuretics from day 1 to day 5 stratified by treatment and sex
288 Clin Res Cardiol (2017) 106:280–292
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Fig. 3 Kaplan–Meier estimates
for 180-day cardio-vascular
mortality with numbers at risk
by treatment and sex
Fig. 4 Physician-assessed signs and symptoms of congestion at day 2 by treatment and sex
Table 4 Association between
moderately or markedly better
dyspnea on the Likert scale at 6,
12 and 24 h and selected
characteristics (n = 1076)
Covariates Coefficient (95% CI) Std. err Odds ratio (95% CI) p value
Male -0.5032 (-0.8053, -0.2011) 0.1541 0.605 (0.447, 0.818) 0.0011
HFpEF (LVEF C50) -0.1579 (-0.4959, 0.1801) 0.1725 0.854 (0.609, 1.197) 0.3598
Age -0.0200 (-0.0330, -0.0070) 0.0066 0.980 (0.968, 0.993) 0.0026
Pulse pressure -0.0025 (-0.0113, 0.0064) 0.0045 0.998 (0.989, 1.006) 0.5861
Heart rate 0.0055 (-0.0041, 0.0152) 0.0049 1.006 (0.996, 1.015) 0.2607
Total diuretic dosea -0.0031 (-0.0053, -0.0009) 0.0011 0.997 (0.995, 0.999) 0.0067
Logistic regression model to estimate the relationship between the dependent variable and the covariates
a Total diuretic dose is defined as IV loop diuretics dose ? 0.5 9 oral loop diuretics on day 1
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Limitations
All limitations of retrospective subgroup analyses apply to
our study. No hypotheses regarding sex differences have
been pre-specified, the ratio of men to women is unbal-
anced and, thus, our results could be biased. All results
only have a hypothesis-generating character. The great
majority of the women were white (i.e., 95%), so that
results are not generalizable to black women, an increasing
proportion of the heart failure population with high likeli-
hood for poor outcomes. Also, validation of the VAS and
the Likert scale in acute heart failure is largely based on
data from men and lacking sex-specific validation.
Conclusion
Women exhibit better earlier dyspnea relief and improve-
ment in general wellbeing as compared with men, even
adjusted for age and left ventricular ejection fraction.
However, in-hospital and post-discharge clinical outcomes
were similar between men and women.
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Appendix
See Tables 5 and 6.
Table 5 Interaction analysis of sex and treatment interaction
(unadjusted) (n = 1161)
Outcome p value for interactiona
sex by treatment
All-cause death through day 180 0.7229
CV death through day 60 0.7151
Days alive and out of hospital
through day 60
0.2473
CV death or HF/RF rehospitalization
through day 60
0.7247
RF rehospitalization through day 60 0.9933
HF rehospitalization through day 60 0.8778
Worsening heart failure through day 5 0.6764
SCr increase of C0.3 mg/dL above
baseline through day 5
0.0585
Dyspnea VAS AUC to day 5 0.9228
Time to moderately or markedly better
dyspnea through day 5 (days)
0.2050
Dyspnea Likert scale moderately/marked
better at 6, 12, and 24 h
0.3869
a Interaction p value comes from multiple linear regression models
for continuous outcomes, logistic regression models for categorical
outcomes, Cox proportional hazards models for time-to-event
outcomes T
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